Overview
Affectis is a biopharmaceutical company focusing on the development and commercialisation of novel drugs against depression, bipolar affective disorders, and anxiety.
The company is capitalising on pioneering research made by its founders regarding entirely new pathways involved in the etiology of affective disorders. The company is developing drug candidates that target this pathway. These drugs aim to address the increasing need for more comprehensive and faster-acting treatments with fewer side effects.
Affectis was founded in 2002 as a spin-off from the renowned Max-Planck Institute of Psychiatry, a world leader in the field of neuroscientific research and development. A strong team of executives and scientists with long-term industry experience contribute to Affectis´ progress. Affectis has raised its third round of venture financing in October 2006, led by AESCAP Ventures. The Company is based in Munich, Germany.
Affectis is a biopharmaceutical company focusing on the development and commercialisation of novel drugs against depression, bipolar affective disorders, and anxiety.
The company is capitalising on pioneering research made by its founders regarding entirely new pathways involved in the etiology of affective disorders. The company is developing drug candidates that target this pathway. These drugs aim to address the increasing need for more comprehensive and faster-acting treatments with fewer side effects.
Affectis was founded in 2002 as a spin-off from the renowned Max-Planck Institute of Psychiatry, a world leader in the field of neuroscientific research and development. A strong team of executives and scientists with long-term industry experience contribute to Affectis´ progress. Affectis has raised its third round of venture financing in October 2006, led by AESCAP Ventures. The Company is based in Munich, Germany.